(Q35551942)

English

Exploratory analysis of a phase III trial of pirfenidone identifies a subpopulation of patients with idiopathic pulmonary fibrosis as benefiting from treatment

scientific article published on 28 October 2011

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

8 August 2017

Exploratory analysis of a phase III trial of pirfenidone identifies a subpopulation of patients with idiopathic pulmonary fibrosis as benefiting from treatment (English)

1 reference

Europe PubMed Central

8 August 2017

phase III clinical trial

0 references

pulmonary fibrosis

1 reference

based on heuristic

inferred from title

idiopathic pulmonary fibrosis

1 reference

based on heuristic

inferred from title

Hiroki Takahashi

8

object named as

Hiroki Takahashi

1 reference

Europe PubMed Central

8 August 2017

author name string

Arata Azuma

1

1 reference

Europe PubMed Central

8 August 2017

Yoshio Taguchi

2

1 reference

Europe PubMed Central

8 August 2017

Takashi Ogura

3

1 reference

Europe PubMed Central

8 August 2017

Masahito Ebina

4

1 reference

Europe PubMed Central

8 August 2017

Hiroyuki Taniguchi

5

1 reference

Europe PubMed Central

8 August 2017

Yasuhiro Kondoh

6

1 reference

Europe PubMed Central

8 August 2017

Moritaka Suga

7

1 reference

Europe PubMed Central

8 August 2017

Koichiro Nakata

9

1 reference

Europe PubMed Central

8 August 2017

Atsuhiko Sato

10

1 reference

Europe PubMed Central

8 August 2017

Shoji Kudoh

11

1 reference

Europe PubMed Central

8 August 2017

Toshihiro Nukiwa

12

1 reference

Europe PubMed Central

8 August 2017

Pirfenidone Clinical Study Group in Japan

13

1 reference

Europe PubMed Central

8 August 2017

publication date

28 October 2011

1 reference

Europe PubMed Central

8 August 2017

Respiratory Research

1 reference

Europe PubMed Central

8 August 2017

12

1 reference

Europe PubMed Central

8 August 2017

143

1 reference

Europe PubMed Central

8 August 2017

https://scigraph.springernature.com/pub.10.1186/1465-9921-12-143

0 references

Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3216874

12 July 2018

Pirfenidone: antifibrotic agent for idiopathic pulmonary fibrosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3216874

12 July 2018

Pirfenidone in idiopathic pulmonary fibrosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3216874

12 July 2018

Effect of interferon gamma-1b on survival in patients with idiopathic pulmonary fibrosis (INSPIRE): a multicentre, randomised, placebo-controlled trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3216874

12 July 2018

Antifibrotic action of pirfenidone and prednisolone: different effects on pulmonary cytokines and growth factors in bleomycin-induced murine pulmonary fibrosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3216874

12 July 2018

Double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3216874

12 July 2018

Effects of pirfenidone on transforming growth factor-beta gene expression at the transcriptional level in bleomycin hamster model of lung fibrosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3216874

12 July 2018

Effects of pirfenidone on procollagen gene expression at the transcriptional level in bleomycin hamster model of lung fibrosis.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3216874

12 July 2018

Pirfenidone inhibits PDGF isoforms in bleomycin hamster model of lung fibrosis at the translational level.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3216874

12 July 2018

Prognostic significance of histopathologic subsets in idiopathic pulmonary fibrosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3216874

12 July 2018

Determinants of survival in idiopathic pulmonary fibrosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3216874

12 July 2018

Effect of pirfenidone on the pulmonary fibrosis of Hermansky-Pudlak syndrome

1 reference

https://api.crossref.org/works/10.1186%2F1465-9921-12-143

21 January 2018

Pirfenidone inhibits NADPH-dependent microsomal lipid peroxidation and scavenges hydroxyl radicals

1 reference

https://api.crossref.org/works/10.1186%2F1465-9921-12-143

21 January 2018

Idiopathic pulmonary fibrosis and pirfenidone

1 reference

https://api.crossref.org/works/10.1186%2F1465-9921-12-143

21 January 2018

Pirfenidone in idiopathic pulmonary fibrosis

1 reference

https://api.crossref.org/works/10.1186%2F1465-9921-12-143

21 January 2018

Open-label compassionate use one year-treatment with pirfenidone to patients with chronic pulmonary fibrosis.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3216874

26 September 2018

From the authors:

1 reference

https://api.crossref.org/works/10.1186%2F1465-9921-12-143

21 January 2018

American Thoracic Society. Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. American Thoracic Society (ATS), and the European Respiratory Society (ERS)

1 reference

https://pubmed.ncbi.nlm.nih.gov/22035508

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Treatment of idiopathic pulmonary fibrosis with a new antifibrotic agent, pirfenidone: results of a prospective, open-label Phase II study

1 reference

https://pubmed.ncbi.nlm.nih.gov/22035508

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The clinical diagnosis of pulmonary emphysema; an experimental study

1 reference

https://pubmed.ncbi.nlm.nih.gov/22035508

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1186/1465-9921-12-143

1 reference

Europe PubMed Central

8 August 2017

Dimensions Publication ID

0 references

1 reference

Europe PubMed Central

8 August 2017

1 reference

Europe PubMed Central

8 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q35551942&oldid=1921760779"